<DOC>
	<DOCNO>NCT01121302</DOCNO>
	<brief_summary>1 . The main purpose study assess safety tolerability AZD5213 single oral dos . 2 . Another purpose study evaluate pharmacokinetics ( also call PK - study drug enters leave body body act study drug ) AZD5213 blood urine . One group subject study see food affect pharmacokinetics ( PK ) AZD5213 blood urine . They receive AZD5213 fast overnight return clinic receive AZD5213 eat high fat breakfast .</brief_summary>
	<brief_title>Study Investigate Single Ascending Oral Doses AZD5213 Healthy Male Non Fertile Female Subjects</brief_title>
	<detailed_description />
	<criteria>Suitable vein cannulation repeat venipuncture . Male healthy volunteer willing use barrier contraception sexual intercourse , ie condom , even partner use contraceptive method , first day dose 3 month last dosing AZD5213 . Body weight ≥50 ≤100 Kg Body Mass Index ( BMI ) ≥18 ≤30 kg/m2 . History presence clinically significant disease disorder cardiovascular , pulmonary , renal , hepatic , neurological , gastorintestinal psychiatric/mental disorder . History presence gastrointestinal ( include irritable bowel disease ) , hepatic renal disease condition know interfere absorption , distribution , metabolism , excretion drug . Surgery gastrointestinal tract . History previous ongoing psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>AZD5213</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Safety</keyword>
</DOC>